摘要:
The object of the present invention are novel peptide derivatives of diaryl esters of 1 - aminoalkylphosphonic acids and their use as inhibitors of NS3/4A protease expressed by human HCV virus in prophylaxis and therapy of viral hepatitis type C (VHC). The use of inhibitors with irreversible mechanism of inhibition in the treatment of HCV creates the possibility of effective improvement of the therapy inter alia by reducing the time of drug administration and limiting dosing to one drug.
摘要:
Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
摘要:
The present invention refers to processes for preparing (1 S ,3a R, 6aS)-2-[(2Sv)-2-[[(2S)-2- Cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]- N -[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1 H -cyclopenta[c] pyrrol-1-carboxamid via novel cyclic anhydrides as intermediates. The cyclic anhydrides can easily be reacted with cyclopropylamine to provide the intermediates (S)-3-Amino- N -cyclopropyl-2,2-dialkoxyhexanamide and (S)-tert-Butyl (1-(cyclopropylamino)-2,2-dialkoxy-1-oxohexan-3-yl)carbamate. The present invention also refers to intermediates of the process for preparing telaprevir and processes for the synthesis of said intermediates.
摘要:
The present invention refers to peptides of general formula (I) and their salts for dermatological and cosmetic use, in particular for preventing or reducing the signs of cutaneous aging and for the treatment of wounds (i.e. burns, lacerations), skin ulcers, chronic wounds or bedsores.
摘要:
This application pertains to α-boryl isocyanates, wherein the boronate moiety is in the form of an N-methyliminodiacetic acid (MIDA) boronate of the Formula (2) and the utility of said compounds in the synthesis of the borylamide motif (Β-C-N amide ) in the scaffold of biologically-active boropeptides, such as bortezomib, in the enablement of heterocycle synthesis, and in multi-component reactions (MCRs), such as the Ugi and Passerini processes.
摘要:
Tubulysin compounds of the formula (I) where R 1 , R 2 R 3a , R 3b , R 4 , R 5 , W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
摘要:
This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors. In some embodiments, the compounds described herein include one or more moieties that (i) can confer enhanced solubility, permeability, pharmacokinetics and/or pharmacodynamics properties to the compounds when compared with the corresponding epoxy ketone protease inhibitors that do not contain such moieties; and (ii) can be removed in vivo upon administration to a subject.
摘要:
The present application relates to novel processes for preparation of (1S,3a R,6a S)-octahydrocyclopenta[c]pyrrole-1-carboxylic acid and its derivatives; and their use in preparation of Telaprevir.
摘要翻译:提供了优异的二肽基肽酶-IV抑制剂等。 具体提供的是二肽基肽酶-IV抑制剂,降血糖剂和血管内皮功能障碍抑制剂,其各自包含作为活性成分的一种或多种肽,所述肽选自包含(a) - ( d):(a)Ser-Pro-Ala-Gln(SEQ ID NO:1),(b)Gly-Pro-Val-Arg(SEQ ID NO:2),(c)His-Pro-His- His(SEQ ID NO:3)和(d)Ala-Pro-Lys(SEQ ID NO:4)。 还提供了包含由(a) - (c)表示的氨基酸序列中的任一个的新肽:(a)Ser-Pro-Ala-Gln(SEQ ID NO:1),(b)Gly-Pro-Val- Arg(SEQ ID NO:2)和(c)His-Pro-His-Pro-His(SEQ ID NO:3)。